Literature DB >> 12093881

Influenza vaccines: present and future.

Peter Palese1, Adolfo García-Sastre.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12093881      PMCID： PMC151037          DOI： 10.1172/JCI15999

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  36 in total

1.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  C B Bridges; K Fukuda; N J Cox; J A Singleton
Journal:  MMWR Recomm Rep       Date:  2001-04-20

2.  Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo.

Authors:  A Le Bon; G Schiavoni; G D'Agostino; I Gresser; F Belardelli; D F Tough
Journal:  Immunity       Date:  2001-04       Impact factor: 31.745

3.  Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity.

Authors:  T Watanabe; S Watanabe; H Ito; H Kida; Y Kawaoka
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Strategies for inducing protection against avian influenza A virus subtypes with DNA vaccines.

Authors:  S Kodihalli; D L Kobasa; R G Webster
Journal:  Vaccine       Date:  2000-05-22       Impact factor: 3.641

5.  Generation of influenza A viruses entirely from cloned cDNAs.

Authors:  G Neumann; T Watanabe; H Ito; S Watanabe; H Goto; P Gao; M Hughes; D R Perez; R Donis; E Hoffmann; G Hobom; Y Kawaoka
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

6.  Sequence of the 1918 pandemic influenza virus nonstructural gene (NS) segment and characterization of recombinant viruses bearing the 1918 NS genes.

Authors:  C F Basler; A H Reid; J K Dybing; T A Janczewski; T G Fanning; H Zheng; M Salvatore; M L Perdue; D E Swayne; A García-Sastre; P Palese; J K Taubenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  Effect of zanamivir on duration and resolution of influenza symptoms.

Authors:  A S Monto; A B Moult; S J Sharp
Journal:  Clin Ther       Date:  2000-11       Impact factor: 3.393

8.  Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach.

Authors:  J Talon; M Salvatore; R E O'Neill; Y Nakaya; H Zheng; T Muster; A García-Sastre; P Palese
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

9.  Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.

Authors:  J J Treanor; F G Hayden; P S Vrooman; R Barbarash; R Bettis; D Riff; S Singh; N Kinnersley; P Ward; R G Mills
Journal:  JAMA       Date:  2000-02-23       Impact factor: 56.272

Review 10.  Live attenuated vaccines against influenza; an historical review.

Authors:  M D Wareing; G A Tannock
Journal:  Vaccine       Date:  2001-05-14       Impact factor: 3.641
View more
  51 in total

1.  Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection.

Authors:  Zuzana Staneková; Vojtech Mucha; Tatiana Sládková; Hana Blaškovičová; František Kostolanský; Eva Varečková
Journal:  Influenza Other Respir Viruses       Date:  2012-01-12       Impact factor: 4.380

2.  A replication-incompetent PB2-knockout influenza A virus vaccine vector.

Authors:  Sylvia T Victor; Shinji Watanabe; Hiroaki Katsura; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

3.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats.

Authors:  Kemal Karaca; David E Swayne; Deborah Grosenbaugh; Michel Bublot; Amy Robles; Erica Spackman; Robert Nordgren
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

5.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

6.  Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

Authors:  Otfried Kistner; M Keith Howard; Martin Spruth; Walter Wodal; Peter Brühl; Marijan Gerencer; Brian A Crowe; Helga Savidis-Dacho; Ian Livey; Manfred Reiter; Ines Mayerhofer; Christa Tauer; Leopold Grillberger; Wolfgang Mundt; Falko G Falkner; P Noel Barrett
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

7.  Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years.

Authors:  Iman Almansour; Huaiqing Chen; Shixia Wang; Shan Lu
Journal:  Hum Vaccin Immunother       Date:  2013-07-24       Impact factor: 3.452

8.  Structural insights on the potential significance of the twin Asn-residue found at the base of the hemagglutinin 2 stalk in all influenza A H1N1 strains: a computational study with clinical implications.

Authors:  Marni E Cueno; Kenichi Imai; Kuniyasu Ochiai
Journal:  OMICS       Date:  2013-06

9.  A novel bivalent vaccine based on a PB2-knockout influenza virus protects mice from pandemic H1N1 and highly pathogenic H5N1 virus challenges.

Authors:  Ryuta Uraki; Maki Kiso; Kiyoko Iwatsuki-Horimoto; Satoshi Fukuyama; Emi Takashita; Makoto Ozawa; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

Review 10.  Immunogenetics of seasonal influenza vaccine response.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Vaccine       Date:  2008-09-12       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.